September 6-7 , 2022 Cybersecurity Innovation Series (CSIS) – UAE Chapter ///// October 15, 2022 Mr/Miss/Mrs International Fashion Idol of UAE 2022 //// 31 October – 3 November 2022 MENA IPO SUMMIT SERIES – Dubai Edition //// 02 - 03 Nov 2022 Middle East Women Leader’s Summit 2022 //// 15th November 2022 The Maritime Standard Awards 2022 //// 16th November 2022 The Maritime Standard Tanker Conference 2022 //// 21 - 22 Nov 2022 AIM Summit Dubai Edition 2022 //// 25 Nov 2022 EUROPEAN PROFESSIONAL DOCTORATE BUSINESS QUALIFICATION, 7th EDITION GRADUATION CEREMONY \\\\ for more information go to https://www.dubaiglobalnews.com/en/our-partners-events

September 26, 2022

Dubai New Style

News site from Dubai Global News

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with Celltrion, Inc. and Celltrion Healthcare, Inc. (Celltrion) for YuflymaTM (CT-P17), the first adalimumab biosimilar with a high concentration, low-volume and citrate-free formulation.

This latest agreement provides Hikma with exclusive rights to commercialise YuflymaTM in all of its MENA markets, strengthening its strategic partnership with Celltrion. To date, Hikma has launched three of Celltrion’s biosimilar products, Truxima® (rituximab), Remsima® (infliximab) and Herzuma® (trastuzumab), and is in the process of launching a fourth product, subcutaneous formulation of infliximab, Remsima® SC.

“Building a portfolio of high-value, differentiated products continues to be a key focus area for Hikma,” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA. “We are excited to add YuflymaTM to our portfolio, strengthening our offering of biosimilar and innovative biologic products. Celltrion’s strong technical capabilities and our well-established commercial presence continues to help us increase patients’ access to important medicines that help them in their treatment journey for these difficult diseases. This agreement builds on our position as the fourth largest supplier of medicines in MENA and furthers our purpose of putting better health within reach, every day.”

About YuflymaTM (CT-P17)

CT-P17 is the first proposed high concentration, low-volume and citrate-free adalimumab biosimilar. CT-P17 is indicated for the treatment of patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (PsO), paediatric plaque psoriasis (pPsO), hidradenitis suppurativa (HS), Crohn’s disease (CD), paediatric Crohn’s disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV). CT-P17 is a recombinant human monoclonal antibody that contains the active ingredient adalimumab. Adalimumab is a fully human anti–tumour necrosis factor α (anti-TNFα) monoclonal antibody. CT-P17 provides pain-reducing features as it comes with citrate-free formulation, meaning it causes less pain upon injection.
*Source: AETOSWire

 12,376 total views,  2 views today